Amivantamab plus lazertinib can be used, within its marketing authorisation, as an option for untreated advanced non-small-cell lung cancer (NSCLC) in adults whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. (NICE TA1122)

NICE TA1063: For treating hormone receptor (HR)-positive HER2-negative (defined as immunohistochemistry [IHC]0 or IHC1 positive, or IHC2 positive and in situ hybridisation [ISH]1 negative) locally advanced or metastatic breast
cancer in adults that has:

1 or more PIK3CA, AKT1 or PTEN gene alterations

Recurred or progressed after a cyclin-dependent kinase (CDK) 4 and 6 inhibitor plus anaromatase inhibitor.

For treating ROS1-positive advanced non-small-cell lung cancer (TA1021)

NCIE TA1062: For treating unresectable or metastatic urothelial cancer with susceptible FGFR3 genetic alterations in adults after at least 1 line of treatment for unresectable or metastatic cancer that included a PD-1 or PD-L1 inhibitor

Funded by NHS England indications:
Everolimus with lenvatinib for previously treated advanced renal cell carcinoma (NICE TA498)
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Non-commissioned indications:
Cardiac Transplantation (rejection)
Renal Transplantation (rejection)
Renal Cell Carcinoma (advanced 2nd line treatment)
Prevention of organ rejection in people having a liver transplant (NICE TA348)

Fruquintinib can be used as an option at third line or later to treat metastatic colorectal cancer in adults when previous treatment has included:

• fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without anti-vascular endothelial growth factor (VEGF) treatment, and
• Anti-epidermal growth factor receptor (EGFR) treatment if the cancer is RAS wild-type, unless this was not suitable. (NICE TA1079)

For treating locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that has progressed after at least 1 line of systemic treatment

Ribociclib with an aromatase inhibitor can be used, within its marketing authorisation, as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults. Combine the aromatase inhibitor with a luteinising hormone-releasing hormone agonist, unless after menopause as per NICE TA1086.

For treating polycythaemia vera in adults who cannot tolerate hydroxycarbamide

For treating HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults who have had:
1. an anthracycline or a taxane, or both, unless these treatments are not suitable, and
2. endocrine therapy if they have hormone receptor (HR)-positive breast cancer, unless this is not suitable (NICE TA952).

Venetoclax plus obinutuzumab can be used, within its marketing authorisation, as an option for untreated chronic lymphocytic leukaemia (CLL) in adults. It can only be used if the companies provide the technologies according to the commercial arrangements. (NICE TA1119)